diffuse large B-cell lymphoma

So no patients, one, AXI or LISA or TISA.

So we're going to start off with first-line treatment for DLBCL.

As we typically do, we like to present a case just to create clinical context.

So we're going to start off with a 79-year-old female, initially presented in 2025 with an enlarged lymph node in her neck, some shoulder and hip discomfort.

So we're going to talk about specific antibodies and CAR T therapy going forward.

So we'll again start with a case.

So this is an 82-year-old male who received initial treatment with Polar CHP for stage 4 DLBCL.

He presented with skin involvement.

But this is when you have the development of an aggressive large cell lymphoma in a patient who has underlying CLL.

And, I mean, it happens in less than 10% of CLL cases and will mostly present with a DLBCL, although Hodgkin lymphoma and, interestingly, some T-cell lymphomas have been reported.

But that probably goes back to the tumor microenvironment.

Richter transformation is an entire episode, maybe an entire season in and of itself.

And so those will be very interesting to see.

Do they add anything to what's already out there in terms of polar chip and, you know, obviously our CHOP? I think the other thing that I would like to see in the long run, this may not be immediate, are some of the ctDNA MRD analyses in frontline diffuse large B-cell lymphoma patients.

So after they go through regular standard induction therapy, whether or not they're in MRD negative remissions or not.

And if not, can they go on to get CAR T cells on these trials? Will that be great consolidation therapy for them? So that would be very interesting for me in the long run.

And so to have another good tool in the toolbox is very welcome.

And these are good tools.

All right, well, we're going to move on now and talk about diffuse large B-cell lymphoma.

We'll start out with some papers on first-line therapy, then we'll move into bispecific ADCs, and then cell mods of great interest.

But Dr. Jonathan Friedberg did talk about the off-label use of glifadaab here.

Well, if you've not had a chance to check out DLBCL discussion with Dr. Shadman, take a minute to check that out.

See you in the next episode.

We are The Oncology Brothers.

Well, thanks so much for summing it all up, Maziar.

In our conversation of challenging case series for DLBCL with Dr. Matt Lunning and Jill Siles, the emotions was very similar.

That favorable side effect profile for Lysosil when compared to Axisil, but again, faster turnaround time with Axisil.

And again, partnering up for the community physician with the tertiary care center is rather the key.

For those tuning in, let's go over a quick recap from today's discussion.

In today's treatment

algorithm discussion with Dr. Maziar Shadman, we touched on the current treatment landscape for diffuse large B-cell lymphoma, DLBCL.

Upfront, our treatment options include ARCHOP or POLAR-ARCHIP, where the strongest data for use of polituzumab is in ABC subtype.